Oculus Innovative Sciences Inc. (OCLS, Financial) filed Quarterly Report for the period ended 2011-12-31.
Oculus Innovative Sciences Inc. has a market cap of $25.9 million; its shares were traded at around $1.15 with and P/S ratio of 2.7.
We reported gross profit related to our Microcyn products of $1,840,000, or 71% of product revenues, during the three months ended December 31, 2011, compared to a gross profit of $1,078,000, or 54%, in the prior year period. The improved gross profit is the result of higher gross profit margins in all segments. Our margins in Mexico were 75% during the quarter ended December 31, 2011, compared to 54% in the prior year.
Total revenues were $9,393,000 for the nine months ended December 31, 2011 compared to $7,043,000 in the prior year period. Product revenues increased $2,367,000, or 37%, with increases in the U.S, Mexico, Europe, China and India, offset by a slight decline in the Middle East.
We reported gross profit related to our Microcyn products of $6,482,000, or 75%, of product revenues, during the nine months ended December 31, 2011, compared to a gross profit of $4,071,000, or 64%, in the prior year period. The improved gross profit is primarily the result of higher gross profit margins in all business segments as a result of higher revenues. Our margins in Mexico were 79% during the nine months ended December 31, 2011, compared to 70% in the prior year.
Selling, general and administrative expense increased $1,162,000, or 13%, to $10,076,000 during the nine months ended December 31, 2011, from $8,914,000 during the nine months ended December 31, 2010. Primarily, this increase was due to higher stock compensation charges of $403,000 and higher sales related costs in Mexico and Europe.
Read the The complete Report
Oculus Innovative Sciences Inc. has a market cap of $25.9 million; its shares were traded at around $1.15 with and P/S ratio of 2.7.
Highlight of Business Operations:
Revenue in Mexico increased $86,000, or 8%, primarily due to 15% growth in sales of our 5 liter presentations and 2% growth in the 120 ml and 240 ml presentations. The growth in both categories was offset by a 7% strengthening of the Mexican peso. Mexico s revenue growth in local currency was 16% when compared to the prior period.We reported gross profit related to our Microcyn products of $1,840,000, or 71% of product revenues, during the three months ended December 31, 2011, compared to a gross profit of $1,078,000, or 54%, in the prior year period. The improved gross profit is the result of higher gross profit margins in all segments. Our margins in Mexico were 75% during the quarter ended December 31, 2011, compared to 54% in the prior year.
Total revenues were $9,393,000 for the nine months ended December 31, 2011 compared to $7,043,000 in the prior year period. Product revenues increased $2,367,000, or 37%, with increases in the U.S, Mexico, Europe, China and India, offset by a slight decline in the Middle East.
We reported gross profit related to our Microcyn products of $6,482,000, or 75%, of product revenues, during the nine months ended December 31, 2011, compared to a gross profit of $4,071,000, or 64%, in the prior year period. The improved gross profit is primarily the result of higher gross profit margins in all business segments as a result of higher revenues. Our margins in Mexico were 79% during the nine months ended December 31, 2011, compared to 70% in the prior year.
Selling, general and administrative expense increased $1,162,000, or 13%, to $10,076,000 during the nine months ended December 31, 2011, from $8,914,000 during the nine months ended December 31, 2010. Primarily, this increase was due to higher stock compensation charges of $403,000 and higher sales related costs in Mexico and Europe.
Read the The complete Report
